Paragon 28, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Paragon 28, Inc. - overview
Established
2010
Location
Englewood, CO, US
Primary Industry
Medical Devices & Equipment
About
Based in Colorado, US, and founded in 2010 by Albert DaCosta (CEO), Lee Rosenthal, and Frank Bono (CTO), Paragon 28, Inc. operates as a provider of medical care products that help patients with foot and ankle injuries. In August 2020, Paragon 28, Inc. raised an undisclosed amount of Series B funding co-led by MVM Partners and Piper Sandler Companies.
The firm went public in October 2021 under the ticker symbol "FNA" on the New York Stock Exchange. As of 2021, the company has 175 product patents filed and about 1,000 surgeons using Paragon products on a monthly basis. Paragon 28, Inc. develops tailored solutions and tools to treat foot and ankle conditions.
The company provides products by system, which include plating systems, nails, screw systems, hammertoe implants, charcoal systems, staple systems, porous titanium wedges, syndesmosis, total ankle replacement, total talus replacement, and biologics. It also offers products by procedure that include Hallus Valgus, flat root, arthrodesis/deformity correction, fractures, hammertoe, and biologic solutions. Paragon 28 has a comprehensive portfolio that provides its customers with ankle solutions for trauma, arthritis, and limb salvage. The company generated a revenue of approximately USD 110.
98 million in 2020 and USD 106. 28 million in 2019.
Primary Industry
Medical Devices & Equipment
Sub Industries
Healthcare, Chiropractic, Orthopedic & Physical Therapy, Medical Supplies
Website
www.paragon28.com
Verticals
HealthTech, Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Paragon 28, Inc. - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|
| Revenue (USD) | 106,300,000 | 111,000,000 | 147,464,000 | - | - | - |
| % Revenue Growth (YoY) | - | 4.4% | 32.9% | - | - | - |
| EBITDA (USD) | 6,800,000 | 12,000,000 | (1,238,000) | - | - | - |
| Operating Income (USD) | 2,600,000 | 5,600,000 | (10,775,000) | - | - | - |
| Operating Margin | 2.4% | 5.0% | (7.3%) | - | - | - |
| % EBITDA Margin | 6.4% | 10.8% | (0.8%) | - | - | - |
| NET Income (USD) | (1,100,000) | 1,500,000 | (13,693,000) | - | - | - |
| % Net Margin | (1.0%) | 1.4% | (9.3%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.